278650 — HLB BioStep Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapNeutral

Annual income statement for HLB BioStep Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	R2021 December 31st	R2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	46,040	58,520	64,403	86,277	52,814
Cost of Revenue
Gross Profit	33,671	43,133	42,056	53,400	36,410
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	39,307	49,675	50,424	81,212	54,075
Operating Profit	6,733	8,845	13,979	5,065	-1,261
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	5,375	9,471	12,827	-2,345	326
Provision for Income Taxes
Net Income After Taxes	4,554	8,589	11,532	-883	-54.2
Minority Interest
Net Income Before Extraordinary Items
Net Income	4,195	8,302	11,031	-1,008	-164
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	4,195	8,302	11,031	-1,008	-164
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	74.1	120	107	-1.65	-2.19
Dividends per Share